Literature DB >> 20368885

Canadian consensus guidelines for the management of testicular germ cell cancer.

Lori Wood1, Christian Kollmannsberger, Michael Jewett, Peter Chung, Sebastian Hotte, Martin O'Malley, Joan Sweet, Lynn Anson-Cartwright, Eric Winquist, Scott North, Scott Tyldesley, Jeremy Sturgeon, Mary Gospodarowicz, Roanne Segal, Tina Cheng, Peter Venner, Malcolm Moore, Peter Albers, Robert Huddart, Craig Nichols, Padraig Warde.   

Abstract

Entities:  

Year:  2010        PMID： 20368885      PMCID： PMC2845668          DOI： 10.5489/cuaj.815

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  188 in total

1.  Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors.

Authors:  Joel Sheinfeld; Robert J Motzer; Farhang Rabbani; James McKiernan; Dean Bajorin; George J Bosl
Journal:  J Urol       Date:  2003-10       Impact factor: 7.450

2.  Prospective study of follow up alone in stage I teratoma of the testis.

Authors:  G Read; R J Johnson; P M Wilkinson; B Eddleston
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-19

Review 3.  Surgery for a post-chemotherapy residual mass in seminoma.

Authors:  H W Herr; J Sheinfeld; H S Puc; R Heelan; D F Bajorin; P Mencel; G J Bosl; R J Motzer
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

4.  Phase II trial with etoposide (VP16) plus ifosfamide plus high-dose cisplatin (VIhP regimen) in refractory germ cell tumors.

Authors:  J P Droz; V Ribrag; M Ghosn; J Guimares; C Theodore; M Azab; M Ostronoff; M Mahjoubi; A Moran; J Pico
Journal:  Prog Clin Biol Res       Date:  1989

5.  Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.

Authors:  Peter Albers; Roswitha Siener; Susanne Krege; Hans-Uwe Schmelz; Klaus-Peter Dieckmann; Axel Heidenreich; Peter Kwasny; Maik Pechoel; Jan Lehmann; Sabine Kliesch; Kai-Uwe Köhrmann; Rolf Fimmers; Lothar Weissbach; Volker Loy; Christian Wittekind; Michael Hartmann
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

Review 6.  Management of stage I non-seminomatous testicular cancer: a systematic review and meta-analysis.

Authors:  S J Hotte; L A Mayhew; M Jewett; J Chin; E Winquist
Journal:  Clin Oncol (R Coll Radiol)       Date:  2009-10-17       Impact factor: 4.126

Review 7.  Is the blood-brain barrier relevant in metastatic germ cell tumor?

Authors:  Jose M Azar; Bryan P Schneider; Lawrence H Einhorn
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-01       Impact factor: 7.038

8.  Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Is it indicated?

Authors:  P D Simmonds; G M Mead; A H Lee; J M Theaker; K Dewbury; C J Smart
Journal:  Cancer       Date:  1995-02-15       Impact factor: 6.860

9.  Late relapse of testicular cancer.

Authors:  J Baniel; R S Foster; R Gonin; J E Messemer; J P Donohue; L H Einhorn
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

10.  Surveillance following orchidectomy for stage I testicular seminoma.

Authors:  A Horwich; N Alsanjari; R A'Hern; J Nicholls; D P Dearnaley; C Fisher
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640
View more
  17 in total

1.  Salvage chemotherapy for metastatic germ cell tumours: The known unknowns.

Authors:  Aaron R Hansen; Philippe L Bedard
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

2.  CUA-AUA International Fellows Program: San Francisco 2018.

Authors:  Madhur Nayan
Journal:  Can Urol Assoc J       Date:  2018-08       Impact factor: 1.862

3.  Testicular cancer survivors' supportive care needs and use of online support: a cross-sectional survey.

Authors:  Jacqueline L Bender; David Wiljer; Matthew J To; Philippe L Bedard; Peter Chung; Michael A S Jewett; Andrew Matthew; Malcolm Moore; Padraig Warde; Mary Gospodarowicz
Journal:  Support Care Cancer       Date:  2012-03-03       Impact factor: 3.603

Review 4.  Testicular germ cell tumors: pathogenesis, diagnosis and treatment.

Authors:  Christian Winter; Peter Albers
Journal:  Nat Rev Endocrinol       Date:  2010-11-30       Impact factor: 43.330

5.  28-year late spermatic cord relapse of a testicular non-seminomatous germ cell tumour, managed robotically.

Authors:  James R Hayes; Michael A S Jewett; Robert J Hamilton
Journal:  Can Urol Assoc J       Date:  2016-07-12       Impact factor: 1.862

6.  Consolidative high-dose chemotherapy after conventional-dose chemotherapy as first salvage treatment for male patients with metastatic germ cell tumours.

Authors:  Michel Beausoleil; D Scott Ernst; Larry Stitt; Eric Winquist
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

7.  Surveillance for stage I testicular cancer: Maximizing benefit and minimizing harm.

Authors:  Piotr Czaykowski
Journal:  Can Urol Assoc J       Date:  2022-02       Impact factor: 1.862

Review 8.  Clinical dilemmas in local and regional testis cancer.

Authors:  Gregory J Nason; Ricardo A Rendon; Lori Wood; Robert A Huddart; Peter Albers; Lawrence H Einhorn; Craig R Nichols; Christian Kollmannsberger; Lynn Anson-Cartwright; Padraig Warde; Michael A S Jewett; Peter Chung; Philippe L Bedard; Aaron R Hansen; Robert J Hamilton
Journal:  Can Urol Assoc J       Date:  2021-01       Impact factor: 1.862

Review 9.  Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach.

Authors:  Hester Lieng; Padraig Warde; Philippe Bedard; Robert J Hamilton; Aaron R Hansen; Michael A S Jewett; Martin O'malley; Joan Sweet; Peter Chung
Journal:  Can Urol Assoc J       Date:  2017-12-01       Impact factor: 1.862

10.  A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor.

Authors:  P Ravi; K P Gray; E K O'Donnell; C J Sweeney
Journal:  Ann Oncol       Date:  2013-11-24       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.